- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Genetic Immunity (OTCBB: PWRV), a leader in immunotherapy technology, announced the peer-reviewed publication on the Company's groundbreaking nanotechnology and details on its potential for the cure of HIV. The manuscript is entitled "Nanomedicine applications Towards the Cure of HIV" by J. Lisziewicz and E. R. Toke (www.nanomedjournal.com/article/S1549-9634(12)00287-0/abstract).
The Scientists of Genetic Immunity pioneered research for the cure of HIV: in 1999 they described in the New England Journal of Medicine the first patients whose immune system was boosted to control HIV after interruption of his daily drug treatment (www.nejm.org/doi/full/10.1056/NEJM199905273402114). This observation inspired development of a new medicine called DermaVir that boosts the immune system to specifically recognize and kill HIV infected cells. Today, DermaVir is the most advanced nanomedicine developed for the cure of HIV.
"We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product. In contrast to the daily oral drugs, DermaVir is administered a few times a year with four patches. Our Clinical Trials have shows DermaVir to be as safe as a placebo and it induced long-lasting HIV-specific T cell production. Our GIEU006 Phase II trial demonstrated significant killing of HIV-infected cells, producing 70% viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component towards the eradication of HIV," said Dr. Julianna Lisziewicz, CEO of Genetic Immunity.
Eradication of HIV is a difficult goal to achieve, because a reservoir of HIV is established soon after infection and it persists even after years of potent antiretroviral treatment. New drugs under development can activate dormant HIV and flush the virus from the reservoirs. However, activation is not enough, HIV-infected cells must be detected and killed by the immune system. In Hepatitis C, which is caused by a virus transmitted through the blood similarly to HIV, the cure rate is up to 75% because the use of drugs that suppress virus replication and induce the immune system to fight the virus. Up to now the cure of HIV has not been achieved with drugs that suppress the virus. Therefore, DermaVir will be required to induce the immune system to fight HIV and contribute to the cure of HIV/AIDS.
Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV).
About Power of the Dream Ventures, Inc
Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV), is a clinical stage technology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic biologic drugs for the treatment of viral infections, cancer and allergy. Our Langerhans cell targeting nanomedicines are exceptional in both safety and immune modulating activity boosting specific Th1-type central memory T cells. These are essential to eliminate infected cells or cancerous cells, and balance the immune reactivity in response to allergens.
In 1988 Drs. Lisziewicz and Lori founded Genetic Immunity in the US after they described the 1st patient whose immune system was boosted to control HIV after treatment interruption (Lisziewicz et al. New England Journal of Medicine 1999) that lead to the invention of DermaVir. The Company's innovative technology team directed by Dr. Lisziewicz, a champion of immune boosting therapies, is now headquartered in Budapest, Hungary. She has been invited into the Scientific Advisory Board of the HIV Cure Initiative led by Francoise Barre-Sinoussi, Nobel Prize Laureate for her HIV research in 2009. For more information please visit www.geneticimmunity.com
For more information, please click here
Dr. Zsolt Lisziewicz
Chief Operating Officer
Genetic Immunity, Inc.
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers